#BEGIN_DRUGCARD DB00891

# AHFS_Codes:
Not Available

# ATC_Codes:
J01EB04

# Absorption:
Approximately 60-80%

# Biotransformation:
Hepatic.

# Brand_Mixtures:
Foot Rot Boluses (Ethylenediamine Dihydroiodide + Sulfapyridine)
Neutral Sulfa 50 (Sulfamethazine + Sulfapyridine + Sulfathiazole)
Neutral Sulfa 7 (Sulfamethazine + Sulfapyridine + Sulfathiazole)
Trisulfa G Liq (Sulfamethazine + Sulfapyridine + Sulfathiazole)

# Brand_Names:
Adiplon
Coccoclase
Dagenan
Eubasin
Eubasinum
Haptocil
M and B 693
Piridazol
Plurazol
Pyriamid
Pyridazol
Relbapiridina
Ronin
Septipulmon
Streptosilpyridine
Sulfidin
Sulfidine
Thioseptal
Trianon

# CAS_Registry_Number:
144-83-2

# ChEBI_ID:
132842

# Chemical_Formula:
C11H11N3O2S

# Chemical_IUPAC_Name:
4-amino-N-(pyridin-2-yl)benzene-1-sulfonamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
1944827

# Description:
Antibacterial, potentially toxic, used to treat certain skin diseases. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-Infective Agents
Anti-Infectives
Dermatitis herpetiformis suppressant
Dermatologic Agents
Sulfonamides

# Drug_Interactions:
Chlorpropamide	Sulfonamide/sulfonylurea: possible hypoglycemia
Methotrexate	The sulfamide increases the toxicity of methotrexate

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.35

# Experimental_Logs:
-2.7

# Experimental_Water_Solubility:
268 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Sulfapyridine

# HET_ID:
Not Available

# Half_Life:
6-14 hours.

# InChI_Identifier:
InChI=1S/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14)

# InChI_Key:
InChIKey=GECHUMIMRBOMGK-UHFFFAOYSA-N

# Indication:
For the treatment of dermatitis herpetiformis, benign mucous membrane pemphigoid and pyoderma gangrenosum

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D02434

# LIMS_Drug_ID:
891

# Mechanism_Of_Action:
Sulfapyridine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid by means of processing the substrate para-aminobenzoic acid (PABA). Dihydropteroate synthetase activity is vital in the synthesis of folate, and folate is required for cells to make nucleic acids, such as DNA or RNA. So if DNA molecules cannot be built, the cell cannot divide.

# Melting_Point:
192 °C

# Molecular_Weight_Avg:
249.289

# Molecular_Weight_Mono:
249.057197301

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164779050

# Pharmacology:
Sulfapyridine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of <i>p</i>-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.

# Predicted_LogP_Hydrophobicity:
0.84

# Predicted_LogS:
-3

# Predicted_Water_Solubility:
2.35e-01 g/l

# Primary_Accession_No:
DB00891

# Protein_Binding:
Approximately 50% bound to plasma proteins.

# PubChem_Compound_ID:
5336

# PubChem_Substance_ID:
46506991

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00491

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
2-Sulfanilamidopyridin
2-Sulfanilamidopyridine
2-Sulfanilylaminopyridine
2-Sulfapyridine
4-(2-Pyridinylsulfonyl)aniline
4-[(2-Pyridylamino)sulfonyl]aniline
N(sup 1)-2-Pyridylsulfanilamide
N(sup1)-Pyridylsulfanilamide
N-2-Pyridylsulfanilamide
N1-2-Pyridylsulfanilamide
Sulphapyridine

# Synthesis_Reference:
Not Available

# Toxicity:
LD<sub>50</sub> is 15800 mg/kg (orally in rats).

# Update_Date:
2013-02-08 16:19:44 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Sulfapyridine

# pKa_Isoelectric_Point:
8.43

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_1_ID:
4757

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P11712

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
19586630	McDonald M, Mannion C, Rafter P: A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim and Dapsone residues in muscle by ultra-high-performance liquid chromatography-tandem mass spectrometry according to Commission Decision 2002/657/EC. J Chromatogr A. 2009 Nov 13;1216(46):8110-6. Epub 2009 Jun 9.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X53635

# Drug_Target_1_GenBank_ID_Protein:
44284

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
sulI

# Drug_Target_1_Gene_Sequence:
>852 bp
ATGTTACGCAGCAGGGTGACGGTGTTCGGCATTCTGAATCTCACCGAGGACTCCTTCTTC
GATGAGAGCCGGCGGCTAGACCCCGCCGGCGCTGTCACCGCGGCGATCGAAATGCTGCGA
GTCGGATCAGACGTCGTGGATGTCGGACCGGCCGCCAGCCATCCGGACGCGAGGCCTGTA
TCGCCGGCCGATGAGATCAGACGTATTGCGCCGCTCTTAGACGCCCTGTCCGATCAGATG
CACCGTGTTTCAATCGACAGCTTCCAACCGGAAACCCAGCGCTATGCGCTCAAGCGCGGC
GTGGGCTACCTGAACGATATCCAAGGATTTCCTGACCCTGCGCTCTATCCCGATATTGCT
GAGGCGGACTGCAGGCTGGTGGTTATGCACTCAGCGCAGCGGGATGGCATCGCCACCCGC
ACCGGTCACCTTCGACCCGAAGACGCGCTCGACGAGATTGTGCGGTTCTTCGAGGCGCGG
GTTTCCGCCTTGCGACGGAGCGGGGTCGCTGCCGACCGGCTCATCCTCGATCCGGGGATG
GGATTTTTCTTGAGCCCCGCACCGGAAACATCGCTGCACGTGCTGTCGAACCTTCAAAAG
CTGAAGTCGGCGTTGGGGCTTCCGCTATTGGTCTCGGTGTCGCGGAAATCCTTCTTGGGC
GCCACCGTTGGCCTTCCTGTAAAGGATCTGGGTCCAGCGAGCCTTGCGGCGGAACTTCAC
GCGATCGGCAATGGCGCTGACTACGTCCGCACCCACGCGCCTGGAGATCTGCGAAGCGCA
ATCACCTTCTCGGAAACCCTCGCGAAATTTCGCAGTCGCGACGCCAGAGACCGAGGGTTA
GATCATGCCTAG

# Drug_Target_1_General_Function:
Coenzyme transport and metabolism

# Drug_Target_1_General_References:
2163027	Martin C, Timm J, Rauzier J, Gomez-Lus R, Davies J, Gicquel B: Transposition of an antibiotic resistance element in mycobacteria. Nature. 1990 Jun 21;345(6277):739-43.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
133

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
30639

# Drug_Target_1_Name:
Dihydropterate synthase

# Drug_Target_1_Number_of_Residues:
283

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00809	Pterin_bind

# Drug_Target_1_Protein_Sequence:
>Dihydropterate synthase
MLRSRVTVFGILNLTEDSFFDESRRLDPAGAVTAAIEMLRVGSDVVDVGPAASHPDARPV
SPADEIRRIAPLLDALSDQMHRVSIDSFQPETQRYALKRGVGYLNDIQGFPDPALYPDIA
EADCRLVVMHSAQRDGIATRTGHLRPEDALDEIVRFFEARVSALRRSGVAADRLILDPGM
GFFLSPAPETSLHVLSNLQKLKSALGLPLLVSVSRKSFLGATVGLPVKDLGPASLAAELH
AIGNGADYVRTHAPGDLRSAITFSETLAKFRSRDARDRGLDHA

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q49184

# Drug_Target_1_SwissProt_Name:
DHP1_MYCFO

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
6.52

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00891
